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“It a very complicated case,  
a lotta ins, lotta outs” 
 
“The Dude”, The Big Lebowski 
  
ABSTRACT 
Complex interactions between genes and environmental factors may result in 
destruction of the body’s own cells and tissues by the immune system, i.e. 
autoimmunity. Rheumatoid arthritis (RA) is a chronic joint inflammation mediated by 
all arms of the immune system that can lead to tissue destruction and functional 
disabilities. Many genetic variants and environmental factors that affect the immune 
system in RA have been revealed in recent years, however it is still not known precisely 
how they regulate and control autoimmunity. In this work I studied the function and 
specificity of adaptive immunity in RA, and also addressed influences from known 
genetic variants that predispose for disease.  
First, autoantibody responses to several RA-associated citrullinated autoantigens were 
studied in a cohort of patients with established RA. Antibody responses and their 
interrelationships were examined, both in the whole study cohort and following 
stratification to HLA-DRB1 types, since HLA-DRB1 alleles are the strongest genetic 
risk factors known for RA. The autoantibodies were found to be highly specific for RA 
and displayed only limited cross reactivity. HLA-DRB1*04 alleles strongly associated 
with the presence of these autoantibodies both in sera and synovial fluid.  
T cells are believed to be central mediators of RA pathogenesis, however studying T 
cell specificity has been proven difficult. The stinking HLA-DRB1*04 association with 
different anti-citrulline antibody responses encouraged us to revisit T cell recognition 
and responses to citrullinated proteins. We identified an epitope from vimentin that 
binds HLA-DRB1*0401 in its citrullinated but not in its native form and T cell 
recognition and function were investigated. CD4 T cells from both HLA-DRB1*0401 
RA patients and healthy donors recognized citrullinated vimentin. However, T cells 
derived from RA patients secreted higher levels of cytokines, suggesting previous 
activation and/or cytokine dysregulation in RA. This study required a development of 
an assay sensitive enough to allow detection of rare antigen-specific CD4 T cells. 
Having such a tool, we further applied the same method to functionally examine type-II 
collagen (CII)-reactive CD4 T cells from peripheral blood and synovial fluid from 
HLA-DR*04 RA patients. T cells indeed recognized different variants of the 
immunodominant T cell epitope of CII and displayed epitope spreading throughout the 
disease. Synovial fluid derived T cells produced higher levels of inflammatory 
cytokines as compared to blood suggesting local reactivation.  
Many more RA predisposing genetic variants have been identified outside the HLA-
DRB1 locus in recent years. We therefore continued to study the association with 
autoantibody specificities in two independent cohorts of RA patients. Several genetic 
variants were found to control autoantibodies formation; some associated with several 
autoantibodies whereas others exclusively linked with a single fine specificity.  
In summary, our data suggest that both B and T cells selectively respond to 
autoantigens in RA and are controlled by HLA and additional RA-predisposing genes. 
This work emphasizes the importance of multidisciplinary investigation for the 
understanding of interaction between genes and immunity in order to functionally 
explain epidemiological findings. We further hope that our findings regarding T and B 
cell specificities will encourage others to continue in this direction, which may pave the 
road towards specific therapy in patients following precise gene-immune investigation.  
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1 AIMS OF THIS THESIS  
The overall aim of this thesis work was to study B and T cell specificities in RA and to 
examine the contribution and regulation of the HLA-DRB1 region and additional RA-
predisposing genetic variants on autoreactive immune responses in RA.  
 
More specifically the aims of this thesis were: 
1. To study ACPA fine specificities in sera and synovial fluid from patients with 
RA, and to further characterize the division and the interrelation of different 
ACPAs and evaluate the genetic contribution of the HLA-DRB1 type to 
immunity against citrullinated proteins (paper 1 & 2). 
 
2. To define a T cell epitope from the citrullinated candidate autoantigen vimentin, 
and to target and functionally examine citrullinated-vimentin specific T cell in 
RA (paper 3).  
 
3. To study and compare cytokine responses against different variants of the 
immunodominant T cell epitope on type-II collagen in HLA-DR*04 positive 
RA patients’ peripheral blood and synovial fluid (paper 4).  
 
4. To examine the contribution of RA-predisposing genetic variants outside the 
HLA-DRB1 region to antibody responses against citrullinated autoantigens 
(paper 5).  
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2 AUTOIMMUNITY IN RHEUMATOID ARTHRITIS 
2.1 THE IMMUNE SYSTEM AND AUTOIMMUNITY  
The immune system is one of the main defense mechanisms, providing protection 
against various infections and harmful substances such as toxins. The immune system 
is comprised of a variety of effector cells and molecules and can be divided into two 
main arms: innate and adaptive immunity. Having the ability to combat a wide range of 
pathogens the innate arm rapidly responds and clears most immune insults. If needed 
the adaptive immunity joins the defense effort and specifically fights the pathogen. The 
adaptive arm is composed of T and B lymphocytes and develops throughout the 
lifetime of an individual, building an immunological memory. To efficiently protect an 
organism against diseases the immune system must fulfill its four main tasks: 
i. Recognition, and tolerance (towards self)   
ii. Effector function - neutralization and elimination  
iii. Self control and regulation 
iv. Memorizing, specific for the adaptive immune system 
One of the most important features of lymphocytes is the ability to distinguish between 
self and non-self, not permitting an immune response against the body’s own cells and 
tissues. However, the random gene rearrangements occurring during lymphocyte 
development in the central lymphoid organs may generate lymphocytes with forbidden 
affinity to self-antigens. This may lead to a false recognition and a loss of immune 
tolerance to self, allowing an immune response that may eventually lead to 
autoimmunity. Autoimmune diseases are mostly characterized by an inappropriately 
controlled immunity that may result in inflammation and/or functional problems that 
affect one organ or more, where genes and different environmental factors mutually 
contribute to the development of autoimmunity. It is estimated that about 3-5% of the 
population are affected by different autoimmune disease with an overall increasing 
frequencies in women compared to men1,2.  
 
2.2 RHEUMATOID ARTHRITIS  
Rheumatoid arthritis (RA) is a chromic inflammatory disease characterized by joint 
swelling and destruction, leading to severe disabilities and shorter life expectancy due 
to accelerated atherosclerosis3-7 and other co-morbidities. RA is considered an 
autoimmune disease given the presence of autoantibodies such as rheumatoid factor 
(RF) and anti-citrullinated proteins antibodies (ACPA) found in patients with rather 
high specificity8-11. Both systemic and local autoimmune inflammatory load drive the 
progression of the disease. Like many other autoimmune disorders women are more 
affected than men, with an overall prevalence of 0.5 – 1% in most western 
populations12.  
To ensure correct diagnosis RA is defined by a combination of several criteria. The 
American Collage of Rheumatology (ACR) issued a set of criteria used for 
differentiating RA from other inflammatory arthritidies in 198713 (table 1). During 
2010 updated criteria were issued by the ACR and the European League Against 
Rheumatism (EULAR)14. The 2010 criteria are a score-based algorithm, by which a 
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collective score from four categories sets the evaluation (table 2); an overall score of 
 6/10 is needed for classification of a patient as having RA14. The current 
recommendations, however, are to use both sets of criteria when classifying the 
diagnosis of patients that are subject to research.  
 
Table 1 – The ACR Criteria for RA (1987) 
Criterion  Specification   
i. Morning stiffness 1 hour Morning stiffness in and around joints lasting  1 hour 
ii. Arthritis of 3 joints/joint 
groups 
Three or more joints with soft tissue swelling or fluid in14 
possible areas: left and right proximal interphalangeal (PIP), 
metacarpo-phalangeal (MCP), wrist, elbow, knee, ankle, and 
metatarsophalangeal (MTP) joints. 
iii. Arthritis of the hand joints  One or more swollen joints in a wrist, MCP or PIP joint. 
iv. Symmetry of arthritis Simultaneous involvement of the same joint areas.  
v. Subcutaneous nodules Subcutaneous nodules over bony prominences, extensor 
surfaces, or juxta- articular regions. 
vi. Rheumatoid factor (RF) Detected in sera 
vii. Radiographic changes Typical for rheumatoid arthritis on posteroanterior hand and 
wrist radiographs. Must include erosions or unequivocal to the 
involved joints. 
* Criteria 1-4 should be present for at least six weeks. Patients fulfilling  4 out of 7 criteria are 
classified as having rheumatoid arthritis. Patients with two clinical diagnoses are not to be excluded. 
 
Table 2 – the 2010 ACR/EULAR scoring criteria for Classification of RA  
Group A – Joint involvement  Score 
i. 1 large joint* (*refers to shoulder, elbow, hip, knee and ankle) 0 
ii. 2-10 large joints  1 
iii. 1-3 small joints*, with or without involvement of large joints (*refers to the 
MTP and PIP joints, second to fifth MTP joints, thumb PIP joints and wrists 
2 
iv. 4-10 small joints (with or without involvement of large joints) 3 
v. >10 joints (at least one small joint) 5 
  
Group B – Serology (at least 1 test result is needed for classification) Score  
i. Negative RF and negative ACPA 0 
ii. Low-positive RF or low-positive ACPA 2 
iii. High-positive RF or high-positive ACPA 3 
  
Group C – Acute-phase reactants (at least one test result is needed for 
classification) 
Score 
i. Normal CRP (C-reactive protein) and normal ESR (erythrocyte 
sedimentation rate) 0 
0 
ii. Abnormal CRP or normal ESR 1 1 
  
Group D – Duration of symptoms (self-reported) Score 
i. <6 weeks 0 
ii. 6 weeks 1 
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2.3 AUTOIMMUNITY IN RA  
2.3.1 Autoantibodies in RA  
A wide range of autoantibodies with different specificities is found in RA patients’ sera 
and synovial fluid, which reflects the vigorous activity of the immune system in the 
disease. In this work we mainly studied ACPAs, however rheumatoid factor (RF) and 
antibodies against type-II collagen (CII) are also rather specific for RA and have been 
extensively studied in this context.  
2.3.1.1 Rheumatoid factor  
Rheumatoid factor is the most studied autoantibody present in RA patients and its 
discovery back at the late 1930s led to the logical view that RA is an autoimmune 
disease15. It is present in about 2/3 of RA patients and directed towards determinants in 
the Fc region of IgG. The classical RF is IgM, but also IgA- and IgG-RF are found in 
sera and synovial fluid of RA patients. However, RF has rather low specificity for RA. 
It is also found in sera from patients with other rheumatic and chronic inflammatory 
diseases, viral infections and in up to 5% of healthy individuals with increased 
frequency in elderly16,17.  
2.3.1.2 Anti-type-II collagen antibodies  
Anti-type-II collagen (anti-CII) antibodies are found in sera and synovial fluid of RA 
patients, and were first characterized in the mid 1970s18,19. Anti-CII producing B cells 
were also found in the rheumatoid synovium and synovial fluid, indicating that CII 
drives a specific autoimmune response in the rheumatic joint20-22. About 3-27% of RA 
patients develops anti-CII antibodies23-25 and their presence is correlated with disease 
severity and radiological changes24. These frequencies, however, were measured 
against the whole CII. Higher frequencies of anti-CII antibodies were reported when 
antibodies were monitored using triple-helical peptides that represent the 
immunodominant B cell epitopes on CII, i.e. C1, J1 and U126,27. Moreover, monoclonal 
antibodies specifically targeting these epitopes can induce arthritis in mice27,28. 
2.3.1.3 Anti-citrullinated protein antibodies 
Anti-citrullinated proteins antibodies (ACPAs) have attracted lots of attention in recent 
years. ACPAs exclusively target modified epitopes on proteins that underwent 
deimination of arginines and consequently converted to citrulline (this process, i.e. 
deimination is also called citrullination). Citrullination is mediated by a group of 
enzymes denoted peptidylarginine deiminases (PADs)29,30. Five members of the PAD 
family are currently known (PAD1-4 and PAD6), having different tissue distribution29. 
PAD2 and PAD 4 are expressed in rheumatoid synovial membrane31,32, synovial fluid 
cells33 and extracellularly in synovial fluid34. The activity of these enzymes is 
dependent on high calcium concentrations and deimination can thus occur 
intracellularly35, mainly during apoptosis, or extracellularly in calcium-enriched 
environments36. Of note, the conversion of arginine to citrulline also changes its charge 
from +1 to neutral, as PAD removes the arginine’s positively charged amine group36 
(figure 1). Citrullinated proteins were detected in a number of inflamed tissues, 
including arthritic joints37, lungs38,39, extra-articular inflammatory sites in RA39, 
human brain40 and others. No selectivity of citrullination for certain arginine-
containing proteins has been demonstrated to date, and citrullination of many 
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different proteins in the synovia and in the joint, including fibrinogen41, vimentin42,43, 
CII44 and Į-enolase45 have been found. 
 
Figure 1 - Conversion of arginine to 
citrulline by peptidylarginine deiminase 
(PAD), i.e. citrullination. A 
posttranslational calcium-dependent 
enzymatic process results in the loss of 
one positive charge for every arginine 
residue converted to a neutral citrulline. 
Amended from Klareskog et al. Annu. 
Rev. Immunol. 2008 
 
ACPAs are found in approximately 60-70% of RA patients with rather high 
specificity46. About 2% of healthy population are ACPA-positive and relatively few 
patients with other systemic inflammatory diseases47. An overall measurement of 
ACPA levels is rather simply achieved using the anti-CCP (cyclic citrullinated 
peptides) ELISA-based assay, which potentially detects all ACPAs regardless of their 
specificity and currently aids clinical diagnosis of RA14,47. ACPA levels are fairly stable 
during the disease and very few patients shift from being anti-CCP-positive to negative 
and vice versa48,49. Several lines of evidence suggest that ACPAs play a pathological 
role in RA: (i) Anti-CCP antibodies were found in RA sera up to nine years before the 
clinical onset of RA, and increased concentrations of the antibodies were seen as 
individuals approached onset of disease 50. (ii) In line with this, the finding that very 
few patients develop ACPA after disease onset provides an indirect evidence for the 
contribution of the antibodies to the pathogenesis of ACPA-positive RA (iii) Studies 
of ACPA isotypes show a sustained presence of IgM anti-CCP, indicating a 
continuous activation of ACPA-reactive B cells throughout the disease course51; and 
(iv) it was also demonstrated that a transfer of monoclonal antibodies to citrullinated 
fibrinogen enhanced a mild arthritis in the mouse although they could not induce 
arthritis on their own52. 
 
2.3.2 T cell responses in RA 
The precise pathological autoimmune mechanisms that drive RA are still largely 
unknown. Considerable evidence indicate that CD4 T cells are central in the 
pathogenesis of RA53 and possibly other autoimmune diseases. In inflammatory 
arthritis activated effector CD4 T cells stimulate monocytes/macrophages, synovial 
fibroblasts and B cells to produce inflammatory cytokines like IL-1, IL-6 and TNFD, 
and to secret matrix metalloproteinases. This is mediated via cell-surface signaling 
by means of CD69 and CD1154 as well as through the release of cytokines such 
as IFNJ and IL-17 (reviewed in55). B cell stimulation by activated T cells occurs 
via binding of CD154 and CD28 and results in production of antibodies, e.g. 
rheumatoid factors, anti-CII antibodies and ACPAs. However, the identity of the 
antigen(s) that are recognized by CD4 T cells in RA is still unknown. Activated and 
memory T cells are found in large numbers in the synovial tissue and fluid from 
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patients’ inflamed joints. Some express highly homologous T cell receptor (TCR), 
which represent an oligoclonal expansion56. A major genetic contribution to RA comes 
from several alleles within the HLA-DRB1 loci, dominating by HLA-DRB1*0401, 
HLA-DRB1*0404 and HLA-DRB1*0101 in Caucasians57. These alleles, as well as other 
HLA-DRB1*01 and HLA-DRB1*04 subtypes, share a motif in the third hypervariable 
region of the DRE chain and are therefore expected to present similar antigens to CD4 
T cells58, which also contributed to the thought that CD4 T cells are important in RA. 
All HLA-DRB1 alleles having this motif are defined as possessing “shared epitope” 
alleles58 (the SE theory is further discussed in 2.4.1 HLA). An additional indication for 
the importance of T cells in RA originates form the presence of autoantibodies; most 
autoantibodies in RA sera and synovial fluid are of IgG isotype. IgG-producing B cells 
usually get T cell help for their maturation and differentiation. Thus, in genetically 
susceptible individuals T cells may encounter an arthritogenic antigen in the context of 
MHC class-II and initiate autoimmune responses (together with many other cellular and 
humoral compounds) that eventually result in joint inflammation.  
There have been several attempts to find autoreactive T cells and to characterize their 
specificity and function, where CII, aggrecan and human cartilage gp39 have been 
commonly studied59-61. However, a combination of methodological limitations and 
uncertainty regarding the true identity of the antigens has provided severe limitations to 
these studies59. Still, there are few reports on T cell reactivity to CII62,63, heterogeneous 
nuclear ribonucleoprotein A2 (hnRNP-A2, i.e. RA33)64,65 and recent reports on T cell 
reactivity to citrullinated antigens66,67. However, no overall consensus has been 
reached on the potential autoantigens that are involved and the importance of T cells 
in RA has been challenged68. T cell cytokines such as IFNJ and IL-2 are present in 
relatively low concentrations in the joint, whereas macrophages and fibroblast products 
are abundant69. Paracrine and autocrine cytokines network secreted by macrophages 
and synovial fibroblasts were proposed in the 1990s as a mechanism that perpetuate 
synovitis in a T cell-independent manner70. This model could also explain the 
accumulation of T cells to the inflammatory site via chemotaxis. One of the main goals 
of this work was to revisit the question of T cell specificity in RA using new 
technology and collaborative efforts with experts in the field. Finding the antigens and 
the cells that drive the disease may lead to a breakthrough in the understanding of 
autoimmunity in RA and development of specific therapies.  
 
2.4 GENETIC SUSCEPTIBILITY IN RA  
It is long known that the susceptibility to develop RA is heritable. It is supported by 
studies demonstrating a larger disease concordance in monozygotic twins in 
comparison with dizygotic71,72 and estimated to be approximately 60%71. The study of 
genetic risk factors in RA has exploded in the recent years due to advanced genotyping 
techniques and increased knowledge of the human genome. Today, it is feasible to test 
more than a million genetic variations in a single experiment, allowing hypothesis-free 
genetic studies over wide ranges of the human genome. Thus, the list of genes that are 
associated with the risk of RA has increased. However, all newly discovered genetic 
risk factors display only a modest risk for developing RA and do not explain the major 
part of heritability of RA, as they are also rather common in healthy population.  
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2.4.1 HLA   
In a series of studies done in the 1970s Stastny defined the genetic basis for RA 
susceptibility73,74. He reported that mixed lymphocyte reaction from RA patients 
produced relatively low responses in comparison to healthy controls73. Stastny 
brilliantly interpreted that lymphocytes from RA patients share the same or similar 
“lymphocyte-defined determinates”, and further that “this gene appears to be 
increased in patients with RA with respect to non-RA controls and may reflect an 
association of genes within the HLA chromosomal region leading to predisposition 
for the development of RA”. In a short paper in 1978 Stastny showed that 70 percent 
of an RA patient cohort were HLA-DRw4 in comparison to 28 percent of healthy 
controls and therefore concluded that HLA-DRw4 is a genetic risk factor for having 
RA. Until these days HLA is by far the strongest known genetic susceptibility for the 
development of RA.  
The HLA region is comprised of three different clusters; class I and class II that code 
for MHC class I and MHC class II, respectively, which are central in antigen 
presentation to T cells. The class III cluster codes for many other products, mainly 
immune related molecules, such as cytokines and complement components. The class 
II cluster in HLA region includes 5 main loci; HLA-DP, -DQ, -DR, -DM and -DO. 
The genetic variants with the most known profound contribution for RA susceptibility 
are located within the HLA-DR region (i.e. DR*0101, *0102, *0401, *0401, *0405, 
*0408, *1001, and *1401). As mentioned before, these variants are collectively 
known as “shared epitope” (SE) alleles because of their sequence similarity within 
the third hypervariable region (aa70-74: QKRAA, QRRAA, RRRAA). This provides 
a strong rationale for adaptive immunity having a pathogenic role in RA via MHC 
class-II-dependent T cell activation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – a simplified map of the human leukocyte antigen (HLA) region. Amended from Simmonds 
and Gough, British Medical Bulletin 2005; 71: 93-113 
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2.4.2 RA-predisposing genetic variants outside the HLA-DRB1 region  
Additional genes outside the HLA-DRB1 region are likely to contribute to disease 
pathogenesis and heterogeneity, however these have been harder to identify being 
rather common in the population and having modest effects. A polymorphism in the 
PTPN22 gene on chromosome 1 is the second most common genetic predisposition for 
RA and the first known genetic variance outside the HLA region that was found75,76. 
Following this finding additional polymorphisms in non-MHC genes were identified, 
many that are located in proximity to genes with central immune functions. Several of 
those genetic variants associate with ACPA-positive rather than with ACPA-negative 
disease, demonstrating that these are two distinct subsets with similar clinical 
features77. This strengthens the hypothesis for a role of adaptive immunity in RA 
pathogenesis, in particular for the ACPA-positive subset. A list of genes outside the 
HLA-DRB1 locus in which a polymorphism was associated with RA is provided in 
table 3. The contribution of the majority of these genetic variants to the development of 
anti-citrulline immunity in RA was studied in this work.   
 
Table 3 – non-HLA-DRB1 RA risk alleles 
Rs number Gene(s) Major allele Minor allele Risk allele 
rs631478 HTR2A C T C 
rs132867478 HTR2A C T T 
rs54823479 PRDM1 T C C 
rs478100380 CIITA C T T 
rs453521181 PLCL2 G A A 
rs1043190880 CIITA A G G 
rs544167 C2 G T G 
rs1274661381 FCGR2A C T T 
rs481048581,82 CD40 G T G 
rs10498441 NID2 A G A 
rs1049919481 TNFAIP3 C T C 
rs2064476 HLA-DPB2 A G A 
rs70677883 IL2RA C T T 
rs273634084 BLK A G G 
rs26232 C5orf30 C T C 
rs54038681 RAG1 C T C 
rs23170781 TNIP2 G A A 
rs10402677 CEACAM1 G A A 
rs4204181 CDK6 C G G 
rs202430185 DCIR A T T 
rs380730686 IRF5 A C A 
rs1048863187 IRF5 T C C 
rs376184788 TRAF1 A G G 
rs702655189 C5 A C C 
rs1158623881 CD2,CD58 C G G 
rs23173584 CTLA4 G T G 
rs1301759984 REL A G G 
rs39458181 TAGAP T C T 
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Rs number Gene(s) Major allele Minor allele Risk allele 
rs2263484 C21orf74 A C C 
rs668265481 CD244    
rs6859219 ANKRD55 C A C 
rs1303123784 REL A C C 
rs934734 SPRED2 A G G 
rs11676922 AFF3 A T T 
rs308724379 CTLA4 G A G 
rs167854279,90 KIF5A C G C 
rs951500 CCL21 A G A 
rs89218881 ICAM5 C T T 
rs113310491 CLEC4A G T T 
rs198042281 CD28 T C C 
rs1859341 CEACAM8 A G G 
rs308745692 CIITA A G G 
rs2271077 GALNTL2 A G A 
rs2377422 CLEC4A;POU5F1P3 C T T 
rs247660175,76 PTPN22 C T T 
rs281237881 CCL21 A G G 
rs224034093 PADI4 C T T 
rs6416647 CIITA T C C 
rs389074581 MMEL1 T C T 
rs427262681 NHLH2 C T T 
rs10258735 RPA3 A G G 
rs3093023 CCR6 G A A 
rs321825381 IL2RB G A A 
rs682284479,81 IL2 G T G 
rs723402981 PTPN2 A G G 
rs645762081 HLA-DRA G C G 
rs692022094 TNFAIP3 G A A 
rs10413014 CEACAM8 A G G 
rs757486595 STAT4 G T T 
rs10468473 MAP2K4 G A A 
rs10410147 CEACAM8 G A A 
rs1091956381 PTPRC G A G 
rs475031690 PRKCQ G C G 
rs2523451 MICA A G G 
rs645761796 HLA-DQ C T C 
 
2.5 ENVIRONMENTAL FACTORS  
The auto-aggressive nature of the immune system in RA as well as in many other 
autoimmune disorders is affected by the genetic heritability. Likewise, environmental 
factors and complex interactions between genes and environment also influence the 
immune system to some extent. Such interactions may give rise to immune reactions 
that lead to chronic inflammation. Environmental factors such as smoking, diet97, birth 
weight98 and socioeconomic status99 have been shown to increase the risk to develop 
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RA.  
Smoking is so far the most studied environmental risk factor for RA, and was first 
reported in the late 1980s100. More recently, smoking was studied in greater detail and 
specific interactions between HLA-DRB1 SE alleles, smoking and ACPA-positive 
disease were described38 and further confirmed101,102. Thus, in genetically predisposed 
individuals smoking may trigger specific immune responses, which will ultimately 
result in ACPA-positive RA. A deeper search for a possible mechanism by which 
smoking initiates inflammatory immune response showed that smoking induces 
citrullination of protein in the lungs103, and that macrophages and other antigen 
presenting cells (APC) are activated by cigarette smoke104. Thus, it could be 
hypothesized that citrullinated protein are presented by antigen presented cells in the 
lungs following exposure to cigarette smoke and thereby promote an inflammatory 
response or/and brake of immunological tolerance.  
 
2.6 CURRENT HYPOTHESIS FOR AUTOIMMUNINTY IN RA  
The working hypothesis that has been followed throughout this thesis is that the 
adaptive immune system has a central role in the pathogenesis of RA and that both 
genes and environmental factors interact with the immune system and regulate 
immunological outcome. Environmental factors, however, have not been included in 
my studies.  
Our current view for the development of RA can be divided in three stages: 
i. Induction of immune responses - citrullination of protein in the lungs (for ACPA-
positive disease) or an intake of a foreign antigen, which would be further 
processed and presented to T cells in genetically susceptible individuals. This 
stage may start in the lungs as a result of exposure to cigarette smoke or in the 
periphery due to activation of PAD under inflammatory conditions, or 
following exposure to other arthritogenic antigens. 
ii. Pathogenic inflammatory responses in the joint - due to a secondary event (e.g. 
trauma) an unspecific arthritis develops in the joints. Influx of autoaggressive 
cell to the joint, production of autoantibodies and generation of immune 
complexes.  
iii. Chronic RA - joint inflammation becomes chronic with increased influx of 
immune cells and inflammatory cytokine and autoantibodies production.  
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3 RESULTS AND DISCUSSION  
The aim of this thesis work stems from the hypothesis that the adaptive immune system 
plays a major role in RA and contributes to its pathogenesis. Below the main findings 
of this work are discussed, which describe aspects of T and B cells specificities and 
genetic contribution to RA.   
 
3.1 PAPER 1 – MULTIPLE ANTIBODY REACTIVITIES TO 
CITRULLINATED ANTIGENS IN SERA FROM PATIENTS WITH 
RHEUMATOID ARTHRITIS: ASSOCIATION WITH HLA-DRB1 
ALLELES 
Anti-CCP antibodies are highly specific for RA and are found in patients up to 10 years 
before disease onset 50. These antibodies can therefore be used as a specific biological 
marker for RA and have been included in the new classification criteria for RA that 
were issued in 201014 and are used in the clinic for the diagnosis of RA. However, as 
CCP is a generic peptide it cannot be used to study true autoreactive immune responses 
in RA. Therefore, in this work we investigated serum-antibodies toward three RA-
associated autoantigens in their native and citrullinated (cit) form: (i) fibrinogen, (ii) 
alpha-enolase and (iii) type-II collagen. Fibrinogen (fib) is a soluble plasma 
glycoprotein that converts to fibrin during blood coagulation. In this study antibody 
responses against the full-length fib protein were studied. Alpha-enolase is a glycolytic 
enzyme that is expressed in many tissues, and also in activated monocytes45; in this 
work the immunodominant citrullinated peptide-1 from alpha-enolase (i.e. CEP-1, aa5-
21) was used45,105. Type-II collagen (CII) is the main structural protein of the articular 
cartilage. In this work one of several B cell epitopes was investigated, i.e. C1III a triple 
helical construct of aa359-369106,107.  
IgG antibody responses towards CCP and the three RA-associated antigens (fib, alpha-
enolase and C1) were monitored in sera from 291 RA patients and 100 sex and age 
matched healthy individuals. Similarly to anti-CCP, all specific ACPAs (targeting cit-
fib, CEP-1 and citC1III) were also highly specific to RA in comparison to healthy 
subjects. No antibody responses toward fib or alpha-enolase in their native forms were 
detected, whereas as expected26 antibodies against the native form of C1III were present 
in RA sera, but in a lower frequency than those targeting the citrullinated variant. One 
of the current hypotheses regarding the formation of ACPAs coming from our group is 
that exposure to cigarette smoke can trigger citrullination of proteins in the lungs38,108, 
which would then elicit an immune response against newly citrullinated antigenic 
targets. IgA is the main isotype produced in mucosal tissues such as the lungs; thereby 
we have also studied IgA antibody responses to citrullinated proteins. IgA antibodies 
were found against all three citrulline antigens, yet in lower frequencies in comparison 
to IgGs. Interestingly, ACPA-IgA antibodies were only present in ACPA-IgG positive 
patients, which indirectly suggests a link between the two.  
Since these antibodies target an epitope with common characteristic, i.e. citrullination, 
the degree of cross-reactivity between antibodies against cit-fib, CEP-1 and citC1III was 
studied. Overall the antibodies did not cross-react with each other, although low degree 
of cross-reactivity was found in some individuals. This suggests that the different 
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antibody responses against citrullinated antigens are independent and develop 
separately from each other. It was therefore interesting to characterize the relationship 
between different fine specificities and anti-CCP antibodies. Overall, we could 
conclude that ACPAs are confined to the anti-CCP-positive subset. CCP-high patients 
tend to have multiple reactivities against several citrullinated proteins in comparison to 
those having lower lever of anti-CCP. Some of those, however, also express multiple 
autoantibody reactivity. The relationships between the levels of anti-CCP antibodies 
and specific ACPAs are summarized in a heat map (figure 3).  
It has been shown that the SE alleles (HLA-DRB1*01 and HLA-DRB1*04) associate 
with anti-CCP antibodies38,109 and also control their levels (i.e. patients having two SE 
alleles have higher anti-CCP antibody levels than those carry one SE allele, who have 
higher levels from those who have none)110. We therefore examined the effect of HLA-
DRB1*SE alleles on the levels of ACPAs fine specificities. Patients were first divided 
based on the number of copies of SE alleles: (i) no-SE, (ii) having one SE allele, or (iii) 
having two copies. Patients carrying two copies of the SE allele had higher ACPA 
levels from patients carrying one or no-SE alleles. Patients having single SE allele had 
higher ACPA levels from patients who do not have the SE alleles. This was true for all 
three examined fine specificities, demonstrating the control of the SE alleles on ACPA 
levels. However, for citC1III there was only a trend. Next, to address which SE alleles 
have the strongest influence on ACPA levels we divided the patients into three groups 
based on their HLA-DRB1 type: (i) non-SE, (ii) HLA-DRB1*01 and (iii) HLA-
DRB1*04, here DR*01/04 individuals were excluded from the analysis. HLA-
DRB1*04 patients were found to have the highest antibody levels, whereas HLA-
DRB1*01 patients displayed similar ACPA levels to the non-SE epitope group. In 
summary our findings show that although different ACPAs do not cross-react, HLA-
DRB1*04 alleles commonly regulate ACPA levels irrespective of their specificity.  
 
3.2 PAPER 2 – AUTOANTIBODIES TO SEVERAL CITRULLINATED 
ANTIGENS ARE ENRICHED IN THE JOINTS OF RA PATIENTS 
Synovial fluid (SF) is found in the synovial cavities, in close proximity to the articular 
joint. Under inflammatory conditions excess of SF is frequently found in the articular 
joint, which is enriched with mononuclear cells and other cellular substances. However, 
the presence of ACPAs in SF has not been systematically studied in a large well-
characterized RA cohort. In this study the levels of APCAs in SF were examined and 
systematically compared with those in sera. Also, the association of ACPAs in SF with 
HLA-DRB1 alleles was investigated. Two peptides from vimentin (aa2-17 and aa60-
75)111 and a vimentin-based RA-diagnostic test (i.e. mutated citrullinated vimentin – 
MCV)112 were included in this study in addition to the cit-antigens studied in paper 1. 
A simple comparison between the antibody levels in sera and SF demonstrated equal 
levels of anti-CCP and anti-MCV in both compartments. However, the total IgG levels 
measured in SF were approximately half of that in sera. Using the total IgG levels as a 
reference for comparison between the two compartments the proportions of anti-CCP 
and anti-MCV antibodies in SF were found to be significantly higher than in sera. That 
was also true for the other ACPA fine specificities that were monitored, but not for 
anti- TTx (tetanus toxoid) antibodies, which do not associate with the disease. This 
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with several of the HLA-DRB1 SE alleles further support this notion116,117. However, 
very little is known about autoreactive T cells in RA, their specificity and function 
especially with regards to citrulline immunity. Here we took the initiative to study CD4 
T cell responses towards a citrullinated RA-associated autoantigen in HLA-
DRB1*0401 RA patients.  
All SE alleles have two subsequent positively charged amino acids at positions 71 and 
72, which do not allow accommodation and presentation of positively charged peptides. 
Citrullination reduces the electric charge of arginine from positive to neutral, thus may 
allow a binding of a peptide to SE MHC in it citrullinated form rather than in its native. 
Hill et al. were the first to demonstrate that a peptide from vimentin (aa65-77) can 
binds three different SE alleles (DRB1*0101, DRB1*0401 and DRB1*0404) following 
citrullination at R71, but not in its native form. The citrullination however did not affect 
the binding of the peptides to other non-SE alleles, demonstrating a possible role for 
citrullination only in binding to SE MHCs. The citrullinated version of this peptide also 
induced T cell recall responses in DR*04 transgenic mice. Still, the immunogenicity of 
the peptide was not empirically tested in human settings. 
Following our discovery that citrulline immunity is predominantly associated with 
DRB1*04 alleles, we screened vimentin for possible HLA-DRB1*0401 binding 
peptides using a computer algorithm. We identified one peptide that can bind HLA-
DRB1*0401 in its citrullinated form but not in its native, i.e. aa59-78. This peptide has 
three citrullinated sites, R64, R69 and R71 and two possible binding frames, (i) aa59-71 
and (ii) aa66-78. The binding capacities of all three peptides to HLA-DRB1*0401 were 
experimentally tested in vitro. None of the native peptides bound to DRB1*0401, while 
all the citrullinated did. However, when injected into DR0401-IE transgenic mice only 
cit-vim59-71 and cit-vim59-78 but not cit-vim66-78 elicited a proliferative recall T cell 
responses, demonstrating that cit-vim59-71 is the immunodominant region. Importantly, 
none of the corresponding native-vim peptides induced an immune response.  
Following validation, we loaded cit-vim59-78 on MHC-class II tetramers (Tmr) and 
further screened for cit-vim specific CD4 T cells in immunized DR*0401-IE transgenic 
mice. Using Tmr we found cit-vim specific CD4 T cells only in mice that were 
immunized with cit-vim59-78, but not with the native peptide. Next, to study citrulline-
specific T cells in humans, we stained T cells from DRB1*0401 RA patients and 
healthy controls with cit-vim59-78 Tmr. Cells were first stimulated in vitro with cit-
vim59-78 and further expanded with IL-2 before staining with Tmrs. Equal frequencies 
of cit-vim59-78 specific CD4 T cells were found in RA patients and in healthy controls; 
demonstrating that similarly to other autoimmune settings cit-vim autoreactive T cells 
also exist in healthy subjects118-120. This however was the first demonstration of T cells 
responding to citrullinated-antigen in the context of a DRB1*0401 Tmr in humans.  
The finding of citrulline-specific CD4 T cells in humans encouraged us to learn more 
about the function of these autoreactive cells in RA. Thus, we adopted and further 
adjusted an assay that tested both specificity and function of T cells. We compared the 
function of T cells following stimulation with either vim59-78 or cit-vim59-78 in 22 RA 
patients and 9 healthy controls, all HLA-DRB1*0401. Fifty nine percent of the patients 
reacted towards cit-vim59-78 in comparison with 33% of the healthy controls, as 
evaluated by elevated levels of CD154. Also, patients’ T cells secreted significantly 
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higher levels of TNFD and IFNJ upon stimulation with cit-vim59-78, whereas cells from 
healthy controls did not.  
In order to get a wider perspective on the cytokine production following stimulation 
with cit-vim59-78 in RA patients and healthy controls we examined the levels of 16 
cytokines in culture supernatants. Overall, patients’ cells produced higher levels of 
cytokines in comparison to cells from healthy individuals. More specifically, the 
secreted levels of INFJ, IL-2 and IL-10 were significantly higher in patients and IL-1ȕ, 
IL-3, IL-6, IL-9, IL-13, IL-17F, IL-23 and TNFD displayed a trend towards increased 
production in patients in comparison to healthy individuals. Interestingly, similar 
differences in the cytokine production could be observed also following stimulation 
with hemagglutinin (HA).  
In summary, in this work we have shown that T cells from HLA-DRB1*0401 
individuals can recognize a citrullinated peptide from vimentin. Patients’ cells respond 
more vigorously to the identified antigen in comparison to T cells from healthy 
controls.  
 
3.4 PAPER 4 – MULTIFUNCTIONAL T CELL REACTIVITY TO NATIVE 
AND GLYCOSYLATED TYPE-II COLLAGEN IN RHEUMATOID 
ARTHRITIS 
Type-II collagen (CII) is the main structural protein in articular cartilage. Antibodies 
towards several native and citrullinated epitopes on CII can be found in sera and 
synovial fluid of RA patients with rather high specificity121,122. Immune responses to 
CII are, however, subjected to tolerization and therefore T cell responses to human CII 
are harder to monitor in humans than in mice63. Collagen induced arthritis (CIA) is a 
well-established model for RA. Similarly to human RA, CIA is associated with the 
murine MHC class-II molecules Aq123, and both B and T cell immunodominant 
epitopes are similar in mice and man. 
Encouraged by our findings and the methods used in paper 3 to detect T cell specificity 
and function we continued to examine T cell responses to the different variants of CII 
immunodominant epitope, i.e. aa259-273. This T cell epitope contains two lysines at 
positions 264 and 270 that can be hydroxylated and further glycosylated with mono- or 
disaccharides and thus create four different variants; (i) unmodified - CII-K, (ii) 
glycosylated on lysine-264 - CII-Gal264, (iii) glycosylated on lysine-270 - CII-Gal-
270, or (iv) glycosylated on lysine-264 and 270 - CII-Gal264/270. These modifications 
are recognized by T cells and play an important role in the development of CIA in Aq- 
and DR4 expressing mice52,54,55.  
First, we examined whether T cells isolated from DRB1*0401 and DRB1*0404 
patients’ peripheral blood (PB) respond to the different CII259-273 variants. We found 
that T cells responded to all four variants with simultaneous secretion of IL-17, IFNJ 
and IL-2. Patients demonstrated individual preferences towards different variants, but 
overall the responses to peptides with single-glycosylation were favored in a number of 
patients. Next, we compared the responses of T cell derived from both PB and SF 
against CII. We monitored similar T cell responses in both compartments, however SF-
derived T cells secreted significantly higher levels of cytokines, in particular IFNJ. 
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Lastly, we examined whether T cell responses to CII were sustained or varied over 
time. To this aim we tested longitudinally collected cell samples from the PB of 3 RA 
patients. One patient showed a constant CII response over a period of 5 years, while the 
other two demonstrated increased anti-CII T cell responses in matters of magnitude and 
targeting different variants of CII259-273. Thus, T cell responses against CII seem to 
continue develop overtime and may target additional variants of the CII259-273 epitope. 
This work has shown the potential importance of CII in human arthritis. Active T and B 
cell responses against CII occur in patients and are found in periphery and in articular 
joints. It is interesting that both T cells and antibody levels toward CII are increased in 
SF. In this work we have shown that CII-reactive T cells from SF produce higher levels 
of inflammatory cytokines. Likewise, the levels and the frequencies of antibodies 
targeting three native CII B cell epitopes (i.e. J1, C1 and U1) are elevated in SF, 
especially anti-U1 antibodies that were found in 77% of patients’ SF (figure 4A). In 
fact, anti-CII antibodies in SF are present in more than 50% of ACPA-negative RA, a 
subset of RA of which so far little is known concerning adaptive immunity (figure 4B). 
Unlike ACPAs, CII-autoantibodies do not associate with HLA-DR SE alleles, or with 
HLA-DRB1*04. These data thus suggest that reactivity to non-citrullinated CII and 
citrulline immunity are regulated differently in RA patients. However, this was only 
examined in our cohort that includes 290 RA patients and should be further studied.  
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3.5 PAPER 5 – COMMON VARIANTS IN NON-HLA-DRB1 ALLELES 
ASSOCIATE WITH DISTINCT ACPA FINE SPECIFITIES IN RA 
PATIENTS 
In the previous studies that are included in this thesis we focused on HLA-DRB1, as it 
is the main genetic risk factor for RA known today. We have shown that it controls 
anti-citrulline immunity and presents antigens to autoreactive T cells. Still, additional 
allelic variants that associate with the risk of having RA have been revealed in recent 
years, in particular in the CCP-positive subset. However, it is still unknown whether 
these SNPs influence the formation of ACPAs and if there is distinctive genetic 
regulation of different ACPA fine specificities. 
To study whether ACPAs are controlled by additional genetic variants apart of HLA-
DRB1 we used serotype and genotype data from two independent cohorts of RA 
patients: (i) The Epidemiology Investigation of RA (EIRA) cohort, n=1362 and (ii) an 
additional 379 patients cohort (an extension of the cohort studied in papers I and II), 
which includes patients with established RA who are attending the Rheumatology 
Clinic of the Karolinska University Hospital. HLA-DRB1 type and information 
regarding 52 non-HLA-DRB1 RA-associated SNPs as well as ACPA status concerning 
CCP, cit-vimentin (aa60-75), CEP-1 and citC1III were available for the EIRA cohort. 
Fourteen SNPs were found to be associated with the presence of anti-CCP antibodies; 
six exclusively associated with anti-CCP antibodies, while the remaining 8 also 
associated with other ACPA fine specificities. Six SNPs associated with anti-cit-
vimentin antibodies and two of them exclusively linked with cit-vimentin antibody 
response. Five allelic variants associated with CEP-1, all were also associated with 
other ACPAs. Five SNPs also linked with citC1III and four of them were associated also 
with other ACPAs, whereas one was exclusive for citC1III. All genetic variants that 
were found to significantly associate with ACPA are shown in figure 5A.  
Since anti-citrulline immunity is primarily linked with HLA-DR*04 alleles we 
continued to search for additional associations between ACPAs and RA-predisposing 
genes after subdividing our cohort in two different HLA groups: (i) HLA-DR*04 and 
(ii) non-HLA-DR*04. Hereby, additional SNPs were found to associate with antibodies 
against citrullinated antigens. CLEC4A (rs1133104) associated with anti-CCP and 
anti-cit-vimentin antibodies, and C5 (rs7026551) and HTR2A (rs1328674) were 
found in association with cit-vimentin and CEP-1 antibodies. Five additional SNPs 
individually associated with different ACPAs (figure 5B). In the non-HLA-DR*04 
group RPA3 (rs10258735) linked with antibodies against CCP, cit-vimentin and 
CEP-1. CCL21 (rs2812378) associated with anti-CCP and anti-CEP-1 antibodies and 
REL (rs13031237) with anti-CCP and anti-citC1III antibodies. Ten additional SNPs 
exclusively associated with the different ACPAs (figure 5C).  
In order to replicate these potentially interesting findings, we examined the identified 
associations in an independent cohort of 379 RA patients with established disease all 
from Stockholm area. Four genetic variants were replicated; HLA-DQ (rs6457617) 
associated with antibody responses against CCP, cit-vimentin and CEP-1, while 
PTPN22 (rs2476601) was found to be significant in both cohorts for the presence of 
both anti-CCP and anti-cit-vimentin antibodies. HLA-DPB2 (rs2064476) and MICA 
(rs2523451) were only associated with a cit-vimentin response. The inability to 
replicate other allelic variants may be due to a lack of power in our replication cohort 
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CCP Discovery cohort OR (95% CI) 
Replication cohort 
OR (95% CI) 
HLA-DQ (rs6457617) 3.192 (2.267-4.545) 2.696 (1.669-4.429) 
PTPN22 (rs2476601) 5.146 (1.848-22.143) 3.550 (1.003-24.411) 
CDK6 (rs42041) 1.368 (1.056-1.777) 1.404 (0.874-2.285) 
MICA (rs2523451) 1.382 (0.984-1.938) 1.707 (1.039-2.795) 
PRDM1 (rs548234)* 1.350 (0.942-1.940) *for non-HLA-DR*04 
1.797 (0.949-3.442) 
*for non-HLA-DR*04 
PADI4 (rs2240340) 1.763 (1.161-2.688) *for non-HLA-DR*04 
1.627 (0.838-3.176) 
*for non-HLA-DR*04 
 
Cit-vim Discovery cohort OR (95% CI) 
Replication cohort 
OR (95% CI) 
HLA-DPB2 (rs2064476) 1.496 (1.100-2.040) 2.306 (1.492-3.584) 
HLA-DQ (rs6457617) 2.661 (1.959-3.629) 2.146 (1.413-3.280) 
MICA (rs2523451) 1.595 (1.151-2.221) 1.818 (1.162-2.851) 
PTPN22 (rs2476601) 1.278 (1.011-1.615) 1.691 (1.083-2.667) 
TRAF1 (rs3761847) 1.375 (0.965-1.970) 1.406 (0.863-2.289) 
CD28 (rs1980422)* 1.962 (0.825-4.473)  *for non-HLA-DR*04 
3.802 (0.814-29.447) 
 *for non-HLA-DR*04 
 
CEP-1 Discovery cohort OR (95% CI) 
Replication cohort 
OR (95% CI) 
HLA-DQ (rs6457617) 2.145 (1.583-2.914) 1.564 (1.037-2.365) 
PTPN22 (rs2476601) 1.369 (1.083-1.733) 1.475 (0.957-2.279) 
CIITA (rs6416647)* 1.485 (1.066-2.073) *for HLA-DR*04 
1.431 (0.833-2.468) 
*for HLA-DR*04 
HTR2A (rs1328674) 1.361 (0.893-2.096) 1.924 (0.854-4.546) 
PRKCQ (rs4750316) 1.204 (0.945-1.534) 1.860 (1.220-2.849) 
 
CitC1III Discovery cohort OR (95% CI)
Replication cohort 
OR (95% CI) 
HLA-DPB2 (rs2064476) 1.306 (0.959-1.785) 1.386 (0.887-2.184) 
HLA-DQ (rs6457617)* 2.769 (1.566-4.930) *for non-HLA-DR*04 
1.874 (0.912-3.837) 
*for non-HLA-DR*04 
CDK6 (rs42041) 1.181 (0.933-1.495) 1.549 (1.012-2.372) 
MMEL1 (rs3890745) 1.319, (0.899-1.959) 1.883 (0.850-4.634) 
TNFAIP3 (rs6920220)* 1.797 (0.960-3.507) *for HLA-DR*04
3.254 (0.991-15.257) 
*for HLA-DR*04 
 
 
Table 4 - Odds ratio and 95% confidence intervals (CI) for the genetic variants that show significant 
association in both cohorts (in black), or a trend towards significant association (marked in gray and 
Italic). Discovery cohort, EIRA (n=1362); Replication cohort, n=379.   
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4 CONCLUSIONS AND REMARKS  
Several findings in this work are in my opinion important and may contribute to the 
understanding of the pathogenic mechanisms that are involved in RA, in particular 
ACPA-positive. Also, the finding of autoreactive T cells and the characterization of 
their function underlines that autoimmunity indeed drives RA, at least a subtype of the 
disease. Also, some of the methods applied here may be utilized to study T cell 
function in health and disease. Below, I highlighted the results that are in my opinion 
the main outcomes of this work: 
i. ACPAs predominantly associate with HLA-DRB1*04 alleles, in particular 
*0401, rather then with other SE alleles, both in sera and synovial fluid. 
ii. Antibodies against different specific citrullinated antigens display only a limited 
cross-reactivity between them.  
iii. The levels of ACPAs are increased in the synovial fluid compared to sera.  
iv. A peptide from vimentin (aa59-78) binds HLA-DRB1*0401 in it’s citrullinated 
form but not in its native. Cit-vim59-78 in vitro activates CD4 T cells and elicits 
secretion of inflammatory cytokines.  
v. CD4 T cells derived from peripheral blood and synovial fluid of HLA-
DRB1*04 RA patients react with several variants of CII259-273. T cells derived 
from synovial fluid are hyper-reactive and produce higher levels of cytokines in 
comparison to those derived from peripheral blood. Also, epitope spreading of 
the different variants of this CII epitope occurs during the disease course.  
vi. This work indirectly provides a proof of concept that autoreactive T cells can be 
enumerated using MHC class-II tetramers. It also presents an additional 
approach to detect rare CD4 T cells and to study their function.   
vii. Non-HLA-DRB1 predisposing allelic variants regulate anti-citrulline immunity; 
some control all or most citrulline specificities that were studied here, while 
others exclusively associate with single ACPA fine specificity. This provides a 
basis for further subgrouping ACPA-positive RA. 
HLA-DRB1*04 alleles represent the strongest genetic predisposition for RA, even 
stronger than other HLA-DRB1*SE alleles although those are also commonly found in 
RA patients in comparison to healthy population. In the first two papers included in this 
work we reported that ACPA associate with HLA-DRB1*04 alleles rather then HLA-
DRB1*01 both in sera and in synovial fluid. This association was first seen in a rather 
small number of RA patients (n=221) and remained in the expanded cohort of 379 
patients. We therefore suggest that anti-citrulline immunity shares common pathways 
as it is tightly linked with HLA-DRB1*04 alleles. Recently, when examining the HLA 
association in a larger cohort of 1362 RA patients (i.e. the EIRA cohort) the HLA-
DRB1*01 locus also showed a positive association with ACPAs; suggesting that 
DRB1*01 alleles are also significant for the development of those antibodies, yet to a 
lesser extent than HLA-DRB1*04.  
Citrulline immunity can be treated and studied as one general immune reaction without 
considering the distinct characters of its specificities. HLA is commonly linked and all 
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different epitopes contain citrulline. Our data suggest that antibodies against the cit-
fibrinogen, cit-vimentin, CEP-1 and citC1III have limited cross reactivity and therefore 
may represent individual and independent immune reactions with unique features. 
Other studies demonstrated that anti-CCP antibodies are a collection of ACPAs124, 
where some antibodies toward specific citrullinated peptides cross-react124,125. 
Conformational differences and the surrounding amino acids residues in those epitopes 
are possibly critical for the binding of the ACPAs and may explain the differences in 
cross reactivity.  
The limited cross reactivity between ACPAs and the fact that patients express different 
compositions of single or multiple antibody reactivity may indicate that additional 
genetic factors apart of HLA-DRB1 region control anti-citrulline immunity (here we 
disregard environmental factors, which may have a critical effect). We were fortunate 
to be able to analyse a set of additional 52 SNPs that genetically predispose to RA in 
the EIRA cohort and to be able to examine our findings in an independent cohort. 
Thirty-one allelic variants were found to associate with anti-citrulline antibody 
response; some linked with anti-CCP antibodies and all/most ACPAs studied here, 
while others exclusively associated with either anti-CCP or one antibody specificity. 
Among all allelic variants linked with the autoantibodies, three SNPs from the HLA 
region showed the strongest association both in the EIRA and the replication cohorts; 
i.e. HLA-DQ (rs6457617), HLA-DPB2 (rs2064476) and MICA (rs2523451). Being 
outside the HLA loci PTPN22 (rs2476601) was exceptional with regards to the other 
three replicated SNPs, and was found to significantly associate with anti-CCP and 
anti-cit-vimentin antibodies in both cohorts.  
Interestingly, the four replicated allelic variants are all related to immune system and 
even specifically linked to T cells function. HLA-DQ and HLA-DP are involved in 
antigen presentation, similarly to HLA-DRB1. However, whether they can also present 
citrullinated antigens like HLA-DRB1 SE alleles is currently unknown. MICA (MHC 
class I-related chain A) stimulates cells via the lectin-like receptor NKG2D that is 
widely distributed on natural killer (NK) cells and T cells (in particular CD8 and JG 
CD4)126. In RA MICA is expressed in synovia and can activate CD4/CD28null T 
cells127, which also express NKG2D128. CD4/CD28null T cells are found in increased 
frequencies in RA patients and other chronic inflammatory disorders. In the light of 
these findings, providing an immunological explanation for MICA predisposition and 
regulation of ACPA is of particular interest and should be further investigated. The 
functional influence of the polymorphism in PTPN22, however, has already begun to 
be revealed. PTPN22 encodes a phosphatase (also referred to as Lyp) that inhibits TCR 
signal transduction. It dephosphorylates autophosphorylation sites on the protein 
tyrosine kinases Lck, Fyn, and Zap70 and thereby inhibits T cell activation129. A 
replacement of C-T alleles at position 1858 predispose RA and results in a single 
substitution of arginine to tryptophan at position 620 of the Lyp protein (Lyp 620W), 
which leads to a gain of function130 (an enhanced inhibitory effect on TCR signaling). 
This mutation was demonstrated to alter both T and B cell function possibly by 
effecting TCR and BCR signaling131,132. The mechanisms by which this allelic variant 
contributes to the development of autoimmunity are still unknown. 
An additional 10 allelic variants outside the HLA loci were close to show significant 
association with ACPAs in both cohorts and would possibly reach significance in a 
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larger cohort (table 4). These SNPs further emphasize the fact that the genetic 
regulation of immunity to citrullinated proteins is partly shared, but not identical for all 
different ACPAs. However it should not be excluded that environmental factors as well 
as interactions between genes and environment also might contribute to the shaping of 
autoantibody profile in RA patients.  
Are the autoantibodies found in sera and synovial fluid pathogenic, and do they 
represent a true autoimmunity towards one or more epitopes that drive the 
pathogenesis? Alternatively, are they fingerprints of vigorous unspecific responses 
mistakenly considered to propagate and maintain chronic inflammation? Accumulating 
evidence suggest that ACPAs are pathogenic and display true autoimmunity47. In this 
work we found that the levels of ACPAs in the synovial fluid are proportionally higher 
in comparison to sera. We also showed that anti-CII antibodies are increased in levels 
and frequencies in synovial fluid, while in contrast the levels of anti-TTx antibodies 
measured in synovial fluid were significantly lower compared to sera. This suggests 
that ACPAs and anti-CII antibodies accumulate in the joint or are locally produced 
there. In the joint, the antibodies can form immune complexes with their respective 
citrullinated/native (arginine-containing) antigen. Such immune complexes may bind 
Fc receptors expressed on APC and will further drive production of inflammatory 
cytokines and an increased presentation of citrullinated or CII epitopes by HLA class II 
molecules to autoreactive T cells. T cells will then continue supporting the growing 
inflammatory process, which will eventually become chronic. Indeed, we demonstrated 
that inflammatory CII-reactive T cells are found in the joint and in the periphery of 
patients with established RA. T cells derived from SF were highly reactive in 
comparison to T cells derived from peripheral blood (PB). However, both PB- and SF-
derived T cells can possibly interact with B cells and provide help for autoantibody 
production either in the inflammatory joint or in peripheral lymph nodes. It is intriguing 
that hyper-reactive CII-specific T cells are found in the synovial fluid where higher 
levels and proportions of anti-CII antibodies are also found. Moreover, the epitope 
spreading displayed by CII-reactive T cells in established disease shows that the 
immunity against this joint-restricted antigen continuously progresses.  
In this work we also described T cell reactivity to citrullinated vimentin in RA patients 
and matched healthy controls carrying HLA-DR*0401. We used computer algorithms 
to predict a possible peptide from vimentin that can bind HLA-DRB1*0401 allele only 
in its citrullinated form and not in its native, and verified it experimentally. The peptide, 
cit-vim59-78, has 3 potential citrullinated sites (R64, R69 and R71) and two possible 
binding frames, i.e. cit-vim59-71 and cit-vim66-78, all display similar binding capabilities 
to HLA-DR*0401. However, recall T cell responses in the mouse was only detected 
against cit-vim59-71 and cit-vim59-78 but not towards cit-vim66-78, suggesting that the 
critical frame is located in the first part of the peptide. Cit-vim66-78 is very similar to the 
cit-vim peptide reported by Hill et al. aa65-77133. The latter bound to SE-alleles 
(DRB1*0101, *0401 and *0404) in its citrullinated form and induced T cell responses 
in similar mice that were used by us. However, there are two major differences between 
the two: (i) our peptide had citrulline at position 69, while Hill’s et al. did not. (ii) A 
(large) leucine at position 70 was replaced by a (small) alanine by Hill and his 
colleagues, probably in order to reduce steric disturbance and to improve binding by 
HLA. These may explain the differences in T cell responses to these two seemingly 
similar peptides.  
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T cells specific to cit-vim59-78 were detected in HLA-DR*0401 RA patients and healthy 
individuals using MHC class-II tetramers. This is a direct proof for the existence of 
citrulline-specific T cells in the periphery. This was further confirmed by detection of 
CD154 and 3 different cytokines and also provided information about the inflammatory 
features of these cells. Autoreactive T cells have been previously found in healthy 
individuals118-120,134. However, there is a lack of systematic comparisons between 
autoreactive T cells from healthy individuals and patients. An analysis of 16 cytokines 
in the culture supernatants following stimulation either with cit-vim59-78 or HA showed 
an excessive cytokine production by patients’ cells in comparison to cells derived from 
healthy individuals. This suggests that the patients’ cells had either encountered the 
antigen before or are largely influenced by genetic variance and/or epigenetic 
modifications. The majority of the patients studied here is ACPA-positive and likely to 
carry allelic variants that predispose for RA. Taken as a whole, our data suggest a 
functional dysregulation that originates from SNPs that are favorably expressed in RA 
patients. The detection of rare autoreactive cells was not at all trivial and time and cell 
samples limitations forced us to postponed a detailed investigation of cit-vim59-78-
reactive T cells in synovial fluid. However, we strongly believe that these can also be 
found in the joint where they encounter their antigen and interact with other cellular 
compounds.  
The importance of T cells in RA, and more specifically of autoreactive T cells, has long 
been debated and challenged. Here we supply substantial proof for the existence of 
autoreactive T cells in blood and synovial fluid of RA patients and further provide an 
insight to their distinctive hyper-reactive inflammatory functions in RA. T cell 
recognition of autoantigen(s) may initiate and/or sustain RA. Following antigen 
stimulation, theses cells can migrate to secondary lymphoid organs or to the joint where 
they proliferate and together with B cells, monocyte/macrophages and fibroblast initiate 
an uncontrolled inflammatory process that will eventually damage cartilage and bone in 
the joint. Having a central role in the pathogenesis of RA it is of interest to study the 
function and the phenotype of autoreactive T cells both in blood and in synovial fluid in 
order to develop future therapeutic approaches to specifically target those cells or their 
function. Attractive targets are CD49d (very late antigen 4, [VLA4]) that facilitates T 
cell trafficking and extravasation to inflamed tissues such as the RA synovium, or the 
chemokine receptor CXCR4 that was previously identified on synovial T cells135. 
Another target would be the interaction between activated T cells and macrophages that 
result in extensive TNFD production, which is a central cytokine in joint inflammation. 
In Summary, autoreactive T cells are found in RA63,64,66,67,134, and express functional 
abnormalities that may stem from different allelic variants. T cell studies in RA ought 
to take a step forward using current and future technologies. RA-associated antigens 
must be further screened for potential T cell epitopes and the patterns of their 
presentation and recognition should be characterized. Only then we will have the 
possibility to study mechanisms and pathways used by autoreactive T cells in the 
periphery while trafficking, and at the site of inflammation.  
Multiple susceptibility genes and environmental factors work in concert and contribute 
to the development of RA. Some are already known yet the mechanisms by which they 
drive the disease are unclear, while others are still beyond our understanding. Our work 
has demonstrated a role for adaptive immunity in RA and further shown that the 
interplay between gene and immunity may have a critical role in shaping autoimmunity 
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and also highlighted the allelic variants that are most significant for anti-citrulline 
immunity. Still, additional antigen-driven autoimmune responses in RA, e.g. anti-CII, 
should be studied in a similar fashion as well as the function of RA predisposing genes. 
A hypothetical summary of development to RA is shown in figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – A hypothetical summary of the development of autoantibody-positive RA in genetically 
predisposed individuals.  
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5 FUTURE PERSPECTIVES  
The overall aim of clinical research is to develop better means of prediction, prevention 
and cure. Better understanding of the patho-immunological mechanisms in RA as well 
as the interactions between gene, immunity and environment will create a framework, 
which will allow the identification of subgroups of RA patients. This will then provide 
new opportunities to specifically target different mechanisms and pathways in more 
homogenous patient groups. Several approaches for therapy are already in clinical use, 
other still to be explored: (i) Alteration of the thresholds of immune activation via 
blockade of stimulatory molecules and cytokines or interference of signaling cascades. 
(ii) Modulation of antigen specific cells and induction of tolerance. (iii) Reconstitution 
of the immune system with stem cells, or (iv) Sparing of target organs by targeting 
different anti-inflammatory agents, matrix metalloproteases or chemokines. In my 
opinion, induction of tolerance to known autoantigen(s) would be a favorable approach 
as it is specific and would presumably not interfere with primary immune function. 
Accordingly, studying specificity in RA, its initiation, regulation and progression is of 
particular interest. 
In this work we studied T cell responses in HLA-DRB1*04 individuals towards a 
single peptide from cit-vim and four variants of the major CII T cell epitope. This is a 
first inventory, but not at all sufficient for therapeutic development. RA is most 
probably driven by numerous antigens, and once the disease is clinically apparent the 
immunologic milieu is highly inflammatory and epitope spreading may occur (as was 
also indicated here). Feitsma et al. also identified two potential T cell epitopes from 
citrullinated vimentin, i.e. aa26-44 and aa415-43367, which are different than the 
peptide described in this work. In an attempt to find additional HLA-DRB1*0401 
binding peptides from vimentin/cit-vimentin we synthesized a set of overlapping 
peptides that cover the whole protein in which each arginine-containing peptide has a 
matched citrulline-containing one. Both the strength of the interactions and the stability 
of the binding to HLA-DRB1*0401 were experimentally examined. Using this 
approach we found ten additional citrullinated peptides that bind HLA-DRB1*0401. 
The ability of our peptide as well as the two citrullinated peptides that were described 
by Feitsma et al. to bind HLA-DRB1*0401 was also confirmed using this approach. 
However, the homologous arginine-containing peptide of cit-vim26-44 also bound to 
HLA-DRB1*0401. A similar screening of additional RA candidate autoantigens is of 
interest and would reveal many more epitopes that can be presented in the context of 
MHC and stimulate T cell. Peptides from alpha-enolase, fibrinogen and CII in their 
native and citrullinated forms are obvious choices. Current technology allows such 
screening to various HLA alleles. Good HLA binders, native or citrullinated, should be 
further used for monitoring T cell responses using similar and improved 
methodological approaches presented here. Not only HLA-DRB1 alleles, but also the 
role of HLA-DQ and -DP should be taken in consideration, as they seems to be central 
in immunity against citrullinated antigens.  
The unique association between susceptibility genes and specific immunity is 
intriguing and should be further investigated in a larger well-defined material. This is 
not trivial though, as similar cohorts with complete genotyping/serotyping information 
are not commonly available. Also, population heterogeneity and methodological 
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differences between different research groups may introduce errors. Still, such studies 
will reveal similarities and distinctions between autoimmune responses and highlight 
the allelic variants that are the most significant for the development of specific 
immunity. Those variants should be also functionally investigated. Importantly, the 
association between gene and immunity studied here were analyzed individually for 
each genetic variant without considering possible interaction between the different 
SNPs and therefore displayed low risk for autoantibody development. We should not 
forget, however, that combinations of multiple susceptibility genes reside together in 
patients and may thus work together. Creativity is needed to define how does a set of 
multiple genes regulates autoimmunity and what is then the risk for disease 
development and/or specific immunological phenotype.  
In summary, in order to find better therapeutic agents and to fit the best suitable therapy 
to each patient a deeper immunological understanding of RA pathogenesis must be 
achieved. One possible way forward to identify unique pathways for potential 
intervention would involve a combined investigation of genes, environment and their 
interactions with the immune system in health and disease.  
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